Multidrug resistance is a leading concern in public health. It describes a complex phenotype
whose predominant feature is resistance to a wide range of structurally unrelated cytotoxic …

Hypoxia, a hallmark of solid tumors, determines the selection of invasive and aggressive
malignant clones displaying resistance to radiotherapy, conventional chemotherapy or …

Proteolysis targeting chimeric (PROTAC) technology is an effective endogenous protein
degradation tool developed in recent years that can ubiquitinate the target proteins through …

Abstract P-glycoprotein (P-gp) is a drug efflux transporter that triggers doxorubicin (DOX)
resistance. In this review, we highlight the molecular avenues regulating P-gp, such as Nrf2 …

Multi-drug resistance (MDR) in cancer cells, either intrinsic or acquired through various
mechanisms, significantly hinders the therapeutic efficacy of drugs. Typically, the reduced …

Since 1984, when paclitaxel was approved by the FDA for the treatment of advanced
ovarian carcinoma, taxanes have been widely used as microtubule-targeting antitumor …

Chemotherapy remains a powerful tool to eliminate malignant cells. However, the efficacy of
chemotherapy is compromised by the frequent emergence of intrinsic and acquired …

Multidrug resistance (MDR) remains one of the major impediments for efficacious cancer
chemotherapy. Increased efflux of multiple chemotherapeutic drugs by transmembrane ATP …

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that
regulates various biological processes, including proliferation, metastasis, angiogenesis …

ATP-binding cassette (ABC) transporters mediate the ATP-driven translocation of structurally
and mechanistically distinct substrates against steep concentration gradients. Among the …